## **Radiomics and Artificial Intelligence Workflow**

Subjects: Radiology, Nuclear Medicine & Medical Imaging

Contributor: Elmira Yazdani, Parham Geramifar, Najme Karamzade-Ziarati, Mahdi Sadeghi, Payam Amini,

Arman Rahmim

Radiotheranostics refers to the pairing of radioactive imaging biomarkers with radioactive therapeutic compounds that deliver ionizing radiation. Given the introduction of very promising radiopharmaceuticals, the radiotheranostics approach is creating a novel paradigm in personalized, targeted radionuclide therapies (TRTs), also known as radiopharmaceuticals (RPTs). Radiotherapeutic pairs targeting somatostatin receptors (SSTR) and prostate-specific membrane antigens (PSMA) are increasingly being used to diagnose and treat patients with metastatic neuroendocrine tumors (NETs) and prostate cancer. In parallel, radiomics and artificial intelligence (AI), as important areas in quantitative image analysis, are paving the way for significantly enhanced workflows in diagnostic and theranostic fields, from data and image processing to clinical decision support, improving patient selection, personalized treatment strategies, response prediction, and prognostication. Furthermore, AI has the potential for tremendous effectiveness in patient dosimetry which copes with complex and time-consuming tasks in the RPT workflow.

radiotheranostics

radiomics

artificial intelligence

SSTR

PSMA

workflow


## 1. Introduction

Radiotheranostics represents a medical paradigm that uses radiopharmaceuticals for targeted radionuclide therapy (TRT), also known as radiopharmaceutical therapy (RPT). The approach involves the use of the same or different radiopharmaceuticals for both therapeutic and imaging purposes, enabling the matched targeting of specific disease sites [1][2][3]. The radiotheranostics paradigm enables the visualization of drug pharmacokinetics in the body, enabling personalized medicine frameworks [1]. Radiotheranostics makes it feasible to customize treatment planning based on individual variations by choosing "the right drug for the right patient at the right time" [4].

This study specifically concentrates on radiotheranostic ligand pairs that selectively bind to somatostatin receptors (SSTRs) and the prostate-specific membrane antigen (PSMA). In general, PSMA expression is higher in prostate cancer (PCa) cells than benign prostate cells, providing a comparatively specific target for patients with this tumor. Moreover, SSTRs are expressed much higher in neuroendocrine tumor (NET) cells or meningiomas than in normal tissues .

Prostate cancer is one of the three most common cancers in the world (7.1% of all cancers), with a high survival rate (a 5-year survival rate of >95%) and high recurrence rates [6][7][8][9]. **Figure 1**A illustrates a simplified disease course for PCa patients. In the first stage, patients are diagnosed through an abnormal serum prostate-specific

antigen (PSA) level, a PCa tumor marker. Most of them will be treated (for example, with radiation therapy or surgery), and their PSA will nearly reach zero. However, some of them will have biochemical recurrences. A significant number of PCa patients will progress to metastatic castrate-resistant prostate cancer (mCRPC). Therefore, there is a growing need for alternative therapeutic strategies for these patients. In this regard, several molecules were tested to target PSMA expressed on the cell surface of mCRPC patients [10].




**Figure 1.** The principle of radiotheranostics in mCRPC patients. **(A)**. The typical timeline of different therapies, including RPT (also known as RLT). **(B)**. PSMA-binding domain, linker, and chelator labeled with Lu-177 deliver ionizing radiation to the tumor.

PSMA is a type II, 750-amino acid transmembrane protein anchored in the cell membrane of prostate epithelial cells [11]. Radiopharmaceuticals targeting PSMA for diagnostic imaging purposes include [68Ga]Ga-PSMA-11, [68Ga]Ga-PSMA-617, [68Ga]Ga-PSMA-I&T, [18F]DCFPyL, [18F]PSMA-1007 or [124I]MIP-1095, [64Cu]Cu-PSMA-617, and [44Sc]Sc-PSMA-617. For therapies, [90Y]Y-J591, [177Lu]Lu-PSMA-617, [177Lu]Lu-PSMA-I&T, [90Y]Y-PSMA-617, [225Ac]Ac-PSMA-I&T, and [225Ac]Ac-PSMA-617 have been used [12][13]. Currently, 68Ga or 18F labeled radioligand binding to PSMA are paramount players in PCa applications [14].

In March 2022, [<sup>177</sup>Lu]Lu-PSMA-617 received Food and Drug Administration (FDA) approval as a treatment option for adult patients with PSMA-positive mCRPC, marketed as Pluvicto<sup>®</sup> [15]. The use of radiolabeled PSMA-targeting ligands provides an important theranostic paradigm, with potential for treating mCRPC patients (**Figure 1**B) [16][17].

A similar scenario exists for neuroendocrine tumors (**Figure 2**). Although the epidemiologic importance of NETs is not as high as that of prostate cancer, NETs consist of 0.5% of all malignancies, and the incidence rate has increased six–fold over the past decades [18][19]. Patients with NETs showing high SSTR expression are appropriate candidates for [68Ga]Ga-/[177Lu]Lu-SSTR applications [20].



**Figure 2.** Schematic overview of radiotheranostics principle in NETs patients and the development of radiopharmaceutical. The chelator labeled with Lu-177 binds to SSTRs and delivers ionizing radiations to destroy tumor cells.

Several PET-labeled peptides, including [<sup>68</sup>Ga]Ga-DOTA-Tyr3 octreotide ([<sup>68</sup>Ga]Ga-DOTA-TATE), [<sup>68</sup>Ga]Ga-DOTA-Phe1 Tyr3 octreotide ([<sup>68</sup>Ga]Ga-DOTA-TOC), [<sup>68</sup>Ga]Ga-DOTA-1-NaI3 octreotide ([<sup>68</sup>Ga]Ga-DOTA-NOC), and [<sup>64</sup>Cu]Cu bound DOTA-TATE and DOTA-TOC are synthesized for diagnostic applications. Additionally compounds such as Lutetium-177 (<sup>177</sup>Lu), Yttrium-90 (<sup>90</sup>Y), and Actinium-225 (<sup>225</sup>Ac) bound DOTA-TATE and DOTA-TOC, are produced for therapeutic purposes. In January 2018, the FDA approved [<sup>177</sup>Lu]Lu-DOTA-TATE for the treatment of SSTR-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs) [<sup>21</sup>]. A complete list of clinically relevant radiotheranostic pairs targeting SSTR and PSMA is shown in **Table 1** [<sup>22</sup>].

**Table 1.** Radiotheranostic pairs and targets in NETs and mCRPC diseases with an emphasis on clinical relevance.

Therapeutic Radioisotopes	Diagnostic Radioisoto SSTRs Target/NET	pes-Pharmaceuticals PSMA Target/mCRPC
<sup>177</sup> Lu	[ <sup>68</sup> Ga]Ga-DOTA-TATE PET	[ <sup>68</sup> Ga]Ga-PSMA-617 PET
	[ <sup>68</sup> Ga]Ga-DOTA-TOC PET	[ <sup>68</sup> Ga]Ga-PSMA-I&T PET
		[ <sup>68</sup> Ga]Ga-PSMA-11 PET
	[64Cu]Cu-DOTA-TATE PET	[ <sup>64</sup> Cu]Cu-PSMA-617 PET
	[64Cu]Cu-DOTA-TOC PET	[ Cujcu-PSIMA-017 PET
	No Clinical Match	[ <sup>18</sup> F]PSMA-617 PET
	No Clinical Match	[ <sup>44</sup> Sc]Sc-PSMA-617 PET
<sup>225</sup> Ac	[ <sup>177</sup> Lu]Lu-DOTA-TATE SPECT	[ <sup>177</sup> Lu]Lu-PSMA-617 SPECT

Therapeutic Radioisotopes	Diagnostic Radioisotopes-Pharmaceuticals SSTRs Target/NET PSMA Target/mCRPC	
	[ <sup>177</sup> Lu]Lu-DOTA-TOC SPECT	
90 <b>Y</b>	[ <sup>177</sup> Lu]Lu-DOTA-TATE SPECT	[ <sup>177</sup> Lu]Lu-PSMA-617 SPECT
	[ <sup>177</sup> Lu]Lu-DOTA-TOC SPECT	[ <sup>177</sup> Lu]Lu-J591 SPECT
	[111In]In-DOTA-TATE SPECT	[ <sup>111</sup> In]In-J591 SPECT
	[111In]In-DOTA-TOC SPECT	

1. Li, T.; Ao, E.C.; Lambert, B.; Brans, B.; Vandenberghe, S.; Mok, G.S. Quantitative imaging for targeteer atmosfiguration and the property of the control of the control

Artificke intellige house, and the potential to potential to potential to the workflow and the state of the potential to the wind to the potential to the sential to the sential to the control to the control to the potential to the control to the c

1. 2. Radiomics and allower kflowers. A.; Anand, B. Theranostics: A treasured tailor for tomorrow. J. Pharm. Bioallied Sci. 2014, 6 (Suppl. S1), S6. In precision medicine, radiomics is currently underway in research based on feature extraction from medical imaging readonics by the housing happaning of the housing of the housing happaning of the housing of the hous

8. Steele, C.B.; Li, J.; Huang, B.; Weir, H.K. Prostate cancer survival in the United States by race and stage (2001 2000). Finding from the CONCORD-2 study. Cancer 2017, 123, 5160–5177.

9. Cooperberg, Medisition out Jermentation roll, Image Post to handling face of Social ate Carnocking. Clin. Oncol. Off. J. Am., Soc. Clin. Oncol. 2005, 23; 8146 8151: Geometrical Statistical Statistical Threshold Analysis

10. Jones, W. Graffiths, P.K.; Barata, P.C.; Pallerup J. PSMA theranostics; Review of PSMA-targeted imaging and radioligand therapy. Cancers 2020, 12, 1367.

Figure 3. Radiomics and AI workflow from image acquisition to radiomics modeling.

- 11. Bearbearrickor Alfaharreamorsiebased daucheasebhreatemaebrandehfar, H. PSMA theranostics: Current status and future directions. Mol. Imaging 2018, 17, 1536012118776068.
- Statistical or intensity features: computed using intensity values in each image region. 12. Ahmadzadehfar, H.; Aryana, K.; Pirayesh, E.; Farzanehfar, S.; Assadi, M.; Fallahi, B.; Shafiei, B.;
  - Ayati N. Amoui M. The Iranian Society of Nuclear Medicine practical guideline on radioligand therapy in metastatic castration-resistant prostate cancer using 177Lu-PSMA. Iran. J. Nucl. Med.
  - 44181e26r Aigh-order features: the image transformation process is essential to obtain these features.
- 13. Shakeri, S.; Askari, E.; Zarehparvar, S.; Farahmandfar, F.; Norouzbeigi, N.; Salek, R.; Aryana, K. Individual features are discarded for dimension reduction through feature selection in the next step. Options include Ga-PSMA-11 PET/CT for staging and patient management of high-risk prostate cancer: A single-intraclass correlation coefficients (ICC), principal component analysis (PCA), least absolute shrinkage and center experience from Iran. Iran. J. Nucl. Med. 2022, 30, 33–39. selection operator (LASSO), recursive feature elimination (RFE), and outputs from machine learning methods (ML).
- 14. Liberini, V.; Laudicella, R.; Balma, M.; Nicolotti, D.G.; Buschiazzo, A.; Grimaldi, S.; Lorenzon, L.; DiffBiant chipmaches are applied no lotte or into the control of t
- regression algorithms if the variables are categorical or continuous, respectively. Classification algorithms are 15. FDA. FDA Approves Pluvicto for Metastatic Castration-Resistant Prostate Cancer. 2022. Available divided into linear and nonlinear models. Logistic regression and support vector machines (SVMs) are two methods online: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pluvicto-of analyzing linear models. metastatic-castration-resistant-prostate-cancer (accessed on 23 March 2022).
- 116. reallation Brookthadenciarest reage hoza (NEAZIO); atraNent encloses to the contraction of the contract for #Salazantafam & t; Editorio halori, unde de Belgilori, ition 9.9 Threchos Minds ip Elserd Ceguras sions alla cital importantic, polytheneral location to the protect acquetasion of the color of the c
- lasso regressions. 17. Harsini, S.; Fallahi, B.; Ziarati, N.K.; Razi, A.; Amini, E.; Emami-Ardekani, A.; Fard-Esfahani, A.; Parizi, M.K.; Farzanehfar, S.; Beiki, D. A Prospective Study on -PSMA PET/CT Imaging in Newly In contrast to supervised learning methods, unsupervised learning approaches do not contain predefined response Diagnosed Intermediate-and High-Risk Prostate Cancer, Asia Ocean, J. Nucl. Med. Biol. 2021, 9, variables, instead, the model finds higgen patterns and insights from the given data. In these procedures, similar data are grouped (clustering), or dimensionality is reduced. Some popular models in this category are K-means 184 Decisios Kidasaciural Equideksiónous), incidificial regulab networks 640 filisa urban concrime que operat momano ent anathreise (GA) at differences? Curr. Oncol. Rep. 2021, 23, 43.
- 19. Taal, B.: Visser, O. Epidemiology of neuroendocrine tumours. Neuroendocrinology 2004, 80 Deep learning (DL) methods have been introduced as a more comprehensive part of ML methods with various (Suppl. S1) 3-7 techniques. Classic neural networks, convolutional neural networks (CNNs), recurrent neural networks, auto-2000 of the politique in exactive resident is stricted on the property of the Chaple pages still Overed, to vice Dad do instention of the condition of the line in a distinction of the line in the condition of the line in the line in the condition of the line in the condition of the line in the line imadiota-dentiurated i perittiden obacifibreat ode vos a adota protocos anotate tales tess. And cleated materi intemprate from 2010 multice 2004-20040t, addressing variability in acquisition and reconstruction protocols is crucial to ensure reproducibility [29]. Accordingly, harmonization procedures have been developed to provide a high 21. FDA. FDA Approves Lutetium Lu, F. 177 Dotatate for Treatment of GEP-NETS. Available online: reproducibility of RFs in multicenter studies. Reuze et al. [30] and Orlhac et al. [31] reviewed the radiomics workflow https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-lutetium-lu-177-and its challenges.
- 22hevalorie of Rousse ale deire anolylde edat. Inceller, (ANIAM) raintask. For beudishe halications of aluating and phalislating. We adjust right and Honor good elimentaphile selected as it with the second eliment of the s

dotatate-treatment-gep-nets (accessed on 26 January 2018).

- Fig2022, 12:a232 based on this guideline, for a prostate cancer patient referred to PET/CT imaging, AI can be applied in a chain from radiochemistry to the physician's report generation 23. Yousefirizi, F.; Decasez, P.; Amyar, A.; Ruan, S.; Saboury, B.; Rahmim, A. Artificial Intelligence-Based Detection, Classification and Prediction/Prognosis in PET Imaging: Towards Radiophenomics. arXiv 2021, arXiv 2110 1033
- 24. Gillies, R. Hricak, F. Radiomics: Images are more than pictures, they are data.

  Radiology 2016, 278, 563.

  Instrumentation & PETICT Image Post-Reconstruction & PETICT Image Petict Image
- 25. Mayerhoefer, M.E.; Matherial angs, G.; Häggström, I.; Szczypiński, R.; Cook, G. Introduction to radiomics. Globusty Med. 2020, 61, 488–495.
- 26. Lambin, P.; Leijenaar, R.T.: Deist, T.M.; Peerlings, D.; De Jong, E.E.; Van Timmeren, J.; Sandulearing Street Caruel R. J. Even, A.J.; Jochems, Radiomics The bridge Deliver medical imaging and personalized medicine. Nat. Rev. Clin. 2ncol. 2017, 4,749-762.
- 27. Ray, S. A quick review of machine learning algorithms. In Proceedings of the 2019 International Conference on Machine Learning Data Data Dud and Parallel Computing (COMITCon), Faridabad, India, 14–16 February 2019; IEEE: New York, NY, USA, 2019; pp. 35–39.
- **Figure 4.** A broad range of Al applications in a chain from radiochemistry to a physician's report generation for a 28. Alzubaidi, L.; Zhang, J.; Humaidi, A.J.; Al-Dujaili, A.; Duan, Y.; Al-Shamma, O.; Santamaria, J.; prostate cancer patient who underwent [68Ga]Ga-PSMA-11 PET/CT scan based on SNMMI Al task-force guideline. Fadhel, M.A.; Al-Amidie, M.; Farhan, L. Review of deep learning: Concepts, CNN architectures,
- challenges, applications, future directions. J. Big Data 2021, 8, 1—74. In the first step, Al could predict drug-target interactions, predict and optimize radiochemical reactions, carry out de 290 No. utmagrates job. Land; obtains it est get unactions and the first step. All could predict drug-target interactions, predict and optimize radiochemical reactions, carry out de 290 No. utmagrates job. Land; obtains it est get unaction to a constitution of the constitu
- 30. Reuzé, S.: Schernberg, A.: Orlhac, F.: Sun, R.: Chargari, C.: Dercle, L.; Deutsch, E.: Buvat, I.; Image analysis can be automated using Al for different tasks, such as lesion detection, segmentation, and Robert, C. Radiomics in nuclear medicine applied to radiation therapy: Methods, pitfalls, and quantification for diagnosis and dosimetry. Moreover, Al has the potential to investigate patterns associated with challenges. Int. J. Radiat. Oncol. Biol. Phys. 2018, 102, 1117–1142. pattent results within large biological and imaging datasets. Additionally, Al can also detect and diagnose. By using 301. Orthadds. In the pattern of an also detect and diagnose.
- clinignade ten new cenaetien atter advice 20121, e164597, 61511 ling, and integrating clinical information from various
- Sources, 32. Bradshaw, T.J.; Boellaard, R.; Dutta, J.; Jha, A.K.; Jacobs, P.; Li, Q.; Liu, C.; Sitek, A.; Saboury, B.; Scott, P.J. Nuclear medicine and artificial intelligence: Best practices for algorithm development. J. Nucl. Med. 2022, 63, 500–510.

Retrieved from https://encyclopedia.pub/entry/history/show/122931